Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.0
2.4
Journals
Children
Special Issues
Advances in the Treatment and Management of Congenital Heart Defects
share announcement

Advances in the Treatment and Management of Congenital Heart Defects

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Cardiology".

Deadline for manuscript submissions: 1 August 2024 | Viewed by 2484

Special Issue Editor

Dr. Jenil Patel

E-Mail Website
Guest Editor
Department of Epidemiology, Human Genetics, and Environmental Sciences, UTHealth Houston School of Public Health, Dallas, TX, USA
Interests: pediatrics; occupational health; perinatal epidemiology; congenital heart defects; birth defects epidemiology

Special Issue Information

Dear Colleagues,

Congenital heart disease (CHD) is the most common birth anomaly, affecting nearly 1% of all live births worldwide. There has been significant progress in the diagnosis and management of CHD in children, which has improved the survival rate and quality of life of these patients. Advances in imaging technologies, such as echocardiography, computed tomography, and magnetic resonance imaging, have enhanced the ability to accurately diagnose CHD and evaluate the severity of the disease. Additionally, advancements in surgical techniques, such as minimally invasive procedures and hybrid approaches, have caused it to be possible to repair complex heart defects in children with fewer complications and shorter hospital stays. In recent years, there has been a growing focus on developing personalized treatment plans for children with CHD, considering the unique characteristics of each patient's heart defect and their individual needs. This Special Issue aims to provide an up-to-date overview of the latest advances in the diagnosis and management of CHD in children, with a focus on personalized medicine, novel therapies, and cutting-edge technologies. It will bring together the expertise of clinicians, researchers, and healthcare providers from around the world to share their insights, experiences, and innovative approaches to improving the outcomes for children with CHD.

Dr. Jenil Patel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric epidemiology
  • perinatal epidemiology
  • childhood chronic conditions
  • birth defects
  • adverse birth outcomes
  • disparities

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 949 KiB  
Article
Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study
by Noa Ofek Shlomai, Gilad Lazarovitz, Benjamin Koplewitz and Smadar Eventov Friedman
Children 2023, 10(9), 1572; https://doi.org/10.3390/children10091572 - 19 Sep 2023
Viewed by 1163
Abstract
Objective: This study aimed to assess the association between treatment characteristics of prostaglandin E1 including initiation time and duration, maximal and cumulative doses, and adverse effects. Design: A retrospective cohort study in which medical records of neonates with duct-dependent lesions were studied for [...] Read more.
Objective: This study aimed to assess the association between treatment characteristics of prostaglandin E1 including initiation time and duration, maximal and cumulative doses, and adverse effects. Design: A retrospective cohort study in which medical records of neonates with duct-dependent lesions were studied for treatment parameters and adverse effects. Multivariable logistic regression model was applied for testing the effect PGE1 variables on outcomes. Main outcome measures: The primary outcomes of this study were association of adverse effects of PGE1 treatment with maximal dose, cumulative dose, and treatment duration. The secondary outcomes included safety of feeding in infants treated with PGE1. Results: Eighty-two infants with duct-dependent lesions receiving PGE1 were included. Several infants who received early PGE1 treatment required ventilation support. Feeds were ceased more often as the cumulative dose and duration of PGE1 treatment increased. Gastrointestinal adverse effects were significantly associated with the cumulative dose of PGE1 and treatment duration. Apneas, hyperthermia, and tachycardia were associated with maximal dose. Our data did not demonstrate a difference in the incidence of NEC associated with characteristics of PGE1 treatment. Conclusion: Cumulative PGE1 dose is associated with gastrointestinal adverse effects in neonates. Lower doses should be considered in neonates expecting prolonged PGE1 treatment. Full article
(This article belongs to the Special Issue Advances in the Treatment and Management of Congenital Heart Defects)
►▼ Show Figures

Figure 1

9 pages, 1357 KiB  
Communication
Association of Myocardial Changes and Gene Expression of the NFATC1 and NFATC4—Calcineurin Signaling Pathway in Children with Bicuspid Aortic Valve
by Andrii Kamenshchyk, Margaryta Gonchar, Valentyn Oksenych and Aleksandr Kamyshnyi
Children 2023, 10(9), 1434; https://doi.org/10.3390/children10091434 - 23 Aug 2023
Viewed by 1005
Abstract
Background: The role of NFATC gene expression in bicuspid aortic valve (BAV) progression is not fully understood. The aim of this study is to determine the significance of NFATC1 and NFATC4 gene expression for myocardial changes in children with BAV. Methods: In 47 [...] Read more.
Background: The role of NFATC gene expression in bicuspid aortic valve (BAV) progression is not fully understood. The aim of this study is to determine the significance of NFATC1 and NFATC4 gene expression for myocardial changes in children with BAV. Methods: In 47 children with BAV, the standard Doppler echocardiographic characteristics were detected, and the expression of the NFATC1 and NFATC4 genes was studied. Results: Posterior wall thickness in diastole (PWTd) and aortic valve peak pressure gradient (AoPPG) in BAV patients were significantly higher compared to healthy controls (PWTd median (min–max), 9 (7–10) mm vs. 7 (6–8) mm; and AoPPG median (min–max), 7.79 (2.98–15.09) mm Hg vs. 2.94 (2.42–3.72) mm Hg). The expression of the NFATC1 gene in BAV children was significantly higher compared to NFATC4 (NFATC1 median (min–max); 70.88 (8.79–106.51) e.u. vs. 7.72 (1.74–22.67) e.u., respectively p < 0.05). A significant correlation of NFATC1 expression with Ao found (R = +0.53, p < 0.05). In BAV patients with PWTd > 8 mm and Ao > 21 mm the NFATC1 expression was significantly higher compared to those with PWTd ≤ 8 mm and Ao ≤ 21 mm (NFATC1 median (min–max); 45.49 (5.01–101.52) e.u. vs. 15.53 (2.36–44.40) e.u., p < 0.05 and 81.11 (20.27–101.10) e.u. mm vs. 12.16 (2.40–45.49) e.u., p < 0.05, respectively). Conclusion: In children with BAV the high expression of the NFATC1 calcineurin signaling pathway gene is associated with elevated PWTd and Ao. Full article
(This article belongs to the Special Issue Advances in the Treatment and Management of Congenital Heart Defects)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop